BRBistuvalli Chandrashekarappa Revanasiddappa

Bistuvalli Chandrashekarappa Revanasiddappa

*This is an algorithmically generated author record based on publicly available information.

Bistuvalli Chandrashekarappa Revanasiddappa has a total of 125 co-authors. Here are the top co-authors by number of shared publications:

  • Sheshagiri R. Dixit

    Computer Aided Drug Design Laboratory, Department of Pharmaceutical Chemistry, JSS College of Pharmacy Mysore, JSS Academy of Higher Education and Research, Mysore, Karnataka, 570015, India

    4 shared publications
  • Sheshagiri R. Dixit

    Computer Aided Drug Design Laboratory, Department of Pharmaceutical Chemistry, JSS College of Pharmacy Mysore, JSS Academy of Higher Education and Research, Mysore-570015, Karnataka, India

    4 shared publications
  • Ashwini Prabhu

    Division of Cancer Research and Therapeutics (CaRT), Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, India

    3 shared publications
  • Banylla Felicity Dkhar Gatphoh

    Department of Pharmaceutical Chemistry, NGSM Institute of Pharmaceutical Sciences of Nitte - Deemed to be University, Paneer, Deralakatte, Bangalore 575018, Karnataka, India

    3 shared publications
  • Durgesh Paresh Bidye

    Computer Aided Drug Design Laboratory, Department of Pharmaceutical Chemistry, JSS College of Pharmacy Mysore, JSS Academy of Higher Education and Research, Mysore, Karnataka, 570015, India

    3 shared publications
  • M. Vijay Kumar

    Institue of Excellence, Vijnana Bhavan, University of Mysore, Mysuru 570006, Karnataka, India

    3 shared publications

Latest Publications

  • Exploring Anti-Breast Cancer Potential and Mechanism of Novel Xanthohumol-Metformin Conjugate by Integrating Network Pharmacology, Molecular Docking and Simulation Approaches

    by Vancha Harish, Sharfuddin Mohd, Goparaju Kavya, B. C. Revanasiddappa, Srikanth Jupudi, V. R. Devatharun

    Natural product scaffolds can be combined with repurposed drugs; so-called conjugate molecules might exhibit improved pharmacology. We designed a conjugate (XN–MT) of xanthohumol (a prenylated chalcone with anticancer properties) and metformin (an antidiabetic drug with reported anticancer effects) and evaluated its potential against breast cancer (BC) using network-based pharmacology, docking, molecular dynamics (MD) simulation and density functional theory (DFT) Studies. Network pharmacology revealed targets associated with cell proliferation, apoptosis, CDK4/2/1 signaling, and metabolic regulation, and identified pathways crucial for breast tumorigenesis and chemoresistance. Molecular docking against high-priority targets, like CDK4, PTGS2, and CDK1, predicted favorable binding affinities and plausible interaction modes for the conjugate. MD simulations (100 ns) for the conjugate showed stable ligand–protein interactions and persistent hydrogen bond networks, supporting the conjugate paper’s predicted binding stability. ADME, toxicity, and DFT analyses provided comprehensive insights into the pharmacokinetic profile and electronic behavior of XN, MT, and XN-MT conjugate. Moreover, DFT calculations on XN–MT showed a lower HOMO–LUMO energy gap, average local ionization, decreased electrostatic potential, lower electron affinity, and higher chemical potential than XN, MT, and Palbociclib, indicating greater reactivity and stronger receptor interactions. This integrative in-silico pipeline supports the XN–MT conjugate as a potential candidate for further in-vitro studies and preclinical development in breast cancer therapy targeting CDK4.

  • Mechanistic Evaluation of Abutilon indicum Extract and Syringaldehyde in Ovalbumin-Induced Airway Inflammation Using Computational and Experimental Approaches

    by B. C. Mamatha, S. Vijaya Kumar, Pavithra Pradeep Prabhu, Akhil Nair, K. Mangala Shenoy, Suvarna Kini, Wilona Loren Lobo, Nitha Naveen Dsouza, Srikanth Jupudi, Ashwini Prabhu, et al.

    Abutilon indicum Linn. is a traditionally used medicinal herb in the treatment of inflammatory diseases. Syringaldehyde (SYD) is a major phytoconstituent of A. indicum. To compare the mast cell stabilizing and anti-asthmatic effects of hydroalcoholic extract of A. indicum (HAEAI) and SYD, and to explore the possible molecular mechanisms. Compound 48/80 (C48/80) induced mesenteric mast cell degranulation in rats was evaluated after 7 days of SYD (25 mg/kg and 50 mg/kg) and HAEAI (200 mg/kg and 400 mg/kg). Anti-asthmatic activity was assessed in ovalbumin (OVA)-induced allergic asthma in mice, with SYD and HAEAI administered during the challenge phase. Inflammatory cell counts in blood and bronchoalveolar lavage fluid (BALF) were quantified. BALF Th2 cytokines (IL-4 and IL-13) and serum OVA-specific IgE were measured by ELISA, and lung histopathology was performed. Network pharmacology, molecular docking, and molecular dynamics simulation were used for mechanistic evaluation. SYD and HAEAI showed a substantial effect by inhibiting C48/80-induced degranulation of mast cells ([Formula: see text] < 0.0001). In OVA-challenged mice, both treatments decreased inflammatory cell infiltration in BALF and blood, compared with the inducer control group, which showed elevated BALF cytokine levels of IL-4 (98.50 ± 6.56 pg/mL) and IL-13 (159.91 ± 9.56 pg/mL); treatment with HAEAI and SYD significantly reduced these inflammatory markers. HAEAI decreased IL-4 levels to 84.95 ± 3.73 pg/mL at the low dose and 67.20 ± 3.02 pg/mL at the high dose, while SYD reduced IL-4 levels to 66.91 ± 3.88 pg/mL and 55.90 ± 3.32 pg/mL at the low and high doses, respectively. Similarly, HAEAI reduced IL-13 levels to 143.50 ± 6.96 pg/mL at the low dose and 91.83 ± 9.06 pg/mL at the high dose, whereas SYD lowered IL-13 levels to 118.42 ± 4.86 pg/mL and 55.69 ± 3.74 pg/mL at the low and high doses, respectively. In addition, serum OVA-specific IgE levels were markedly reduced in the treatment groups compared with the inducer control group (557.84 ± 3.39 ng/mL). HAEAI reduced IgE levels to 378.44 ± 1.94 ng/mL at the low dose and 180.90 ± 1.30 ng/mL at the high dose. SYD also lowered serum OVA-specific IgE levels to 323.56 ± 1.93 ng/mL and 222.15 ± 1.55 ng/mL at the low and high doses, respectively. These findings indicate that both HAEAI and SYD exert significant anti-allergic effects by suppressing Th2 cytokines and reducing OVA-specific IgE production. and improved lung histopathology. In silico analysis showed a multi-target effect on allergic and inflammatory signaling. Following docking, a favorable ligand–protein interaction was observed during simulation. SYD and HAEAI have good mast cell stabilizing and anti-asthmatic effects, likely mediated through suppression of Th2-induced inflammation and multi-targeting allergic signaling pathways.

  • Open Access

    Green Acid Mediated Synthesis of Imidazo[1,2‐a]Pyrimidine–Thiazole/1,3,4‐Thiadiazole Hybrids: Design, Characterization and In‐Vitro Biological Evaluation

    by Dinesha P, Shivakumar Naik, Udayakumar D, Maithilee S. Dhekale, Sampat Parayya Vibhutimath, Rajkumar Reddy Rajula, Revanasiddappa B.C, Nanditha Bhat, Naveena S. Veeranagaiah

    This work reports the design and development of two series of imine‐linked imidazo[1,2‐ a ]pyrimidine‐thiazole/1,3,4‐thiadiazole derivatives using a molecular hybridization approach as anti‐tubercular agents. A total of thirty‐seven new hybrid compounds (B1‐B37) were synthesized and characterized. One final molecule, B20, was structurally confirmed by single‐crystal x‐ray diffraction analysis. All the final compounds (B1‐B37) were tested for activity against the Mycobacterium tuberculosis H37Rv strain. Compounds B5, B26, and B30 exhibited significant inhibitory effects, with MICs of 12.5, 12.5, and 6.25 µg/mL, respectively. All novel final compounds also displayed effective antibacterial action against four bacterial strains S. aureus , E. coli , B. subtilis , and P. aeruginosa . Toxicity tests on mouse fibroblast (L929) cell lines revealed that the highly active anti‐TB compounds (B5, B26, and B30) were nontoxic. Furthermore, the outcomes of the in silico ADME evaluation, DFT analysis, molecular docking studies (targeting CYP121 and InhA), and dynamic simulation demonstrated the potent compounds' great potential as prospective scaffolds for the development of novel antitubercular drugs.

  • Open Access

    Porous organic polymers for sustainable pollutant capture and environmental remediation: recent advances and future perspectives

    by Poornachandra Shamanna Prabhakar, Shivakumar, Asha Danthi, Parveen Shaik, Amgoth Ramesh, T. N. Varshitha, Udaya Kumar Dalimba, B. C. Revanasiddappa

    Environmental pollution, climate change, and increasing demands for sustainable remediation require adsorbents that combine high efficiency with selectivity, stability, and regenerability.

  • Synthesis, and biological evaluation of novel 4-thiazolidinone derivatives as promising antidiabetic agents: In silico and in vivo investigations

    by Banylla Felicity DkharGatphoh, Amgoth Ramesh, Poornachandra Shamanna Prabhakar, Madan Kumar, Natasha N. Aggarwal, Ashwini Somayaji, Chaithra Raviraj, Sheshagiri R. Dixit, Durgesh Paresh Bidye, B.C. Revanasiddappa

  • Pyrimidine-Based Compounds in Tuberculosis Management: A Review of their Biological and Medicinal Importance

    by Deepshikha Singh, Vikram Singh, Afrasim Moin, Manu Gangadhar, Bistuvalli Chandrashekarappa Revanasiddappa, Sheshagiri R. Dixit

    Pyrimidine derivatives are a class of chemically and biologically active heterocyclic compounds promising for developing anti-tubercular, anti-viral, anti-malarial, anti-inflammatory, and enzyme-inhibiting drugs. To cure TB, scientists were driven to establish novel pyrimidine derivatives. The main objective of the current review is to identify and develop new pyrimidine moiety- containing derivatives that have been assessed for their structure-activity relationship (SAR). Several drug-resistant MTB infections have emerged and spread worldwide, which has rendered first-line medication ineffective. It is crucial to develop new anti-TB drugs that are extremely effective against both drug-sensitive and drug-resistant TB. The development of pyrimidine therapeutic methods will thus benefit from the current review. Three medications-GSK-286, TBA-7371, and SPR-720 are now undergoing clinical testing. This study aims to emphasize the structural variety of anti-tuberculosis pyrimidine-containing compounds by providing an overview of current developments in drug discovery investigations.

  • Riboflavin and Thymine from Abutilon indicum Linn. Mitigate Allergic Responses: An Integrated network pharmacology, In-silico analysis, MD Simulation, In vitro and Ex vivo Studies

    by B. C. Mamatha, Sharfuddin Mohd, Vancha Harish, Ashwini Prabhu, Durgesh Paresh Bidye, Sheshagiri R. Dixit, B. C. Revanasiddappa, Aravinda Pai, Shareef Shaik

    Abutilon indicum Linn., commonly known as Indian mallow, is known for its diverse pharmacological properties. This study investigates the anti-allergic and protective effects of hydro alcoholic extract of A. indicum (HAEAI) and two bioactive compounds, riboflavin and thymine, from A. indicum, using both in vitro and in vivo models. Cytotoxicity of these molecules was evaluated through the MTT assay on RBL-2H3 cells. Additionally, their anti-allergic effects were assessed using an ex vivo study, evaluating mast cell degranulation induced by Compound 48/80 in rat mesentery and the percentage protection of mast cells was quantified. Ionomycin was used to stimulate RBL-2H3 cells and mediator release. The degranulation levels of the compounds were assessed using the [ ]-hexosaminidase and histamine release assay. Additionally, the expression levels of cytokines, including TNF-[ ], IL-4, IL-6 and IL-13, were quantified using ELISA. The network consisting of composition, targets, and disease has been established. Gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed. Molecular docking techniques were used to simulate the binding affinity of active compounds to target proteins, while molecular dynamics were applied to validate the results obtained from the molecular docking. Riboflavin, Thymine and extract were found to be non-toxic on RBL-2H3 cells. Results demonstrated inhibition of the allergic response induced by Ionomycin. Hence, these two compounds present in Abutilon indicum Linn., emerged as potential drug candidates and can be used in the management of allergic conditions.

  • Open Access

    Exploring the therapeutic potential of some alkaloidal phytoconstituents for diabetes management: a thorough in-silico approachment

    by Nanditha Bhat, B. C. Revanasiddappa, S. Daksha, Disha Chouta, Durgesh Paresh Bidye, Sheshagiri R. Dixit, Abhimanyu Awasthi

    Background: The efficacy of synthetic drugs in the treatment of diabetes mellitus often falls short, limiting their use to symptom management. Consequently, there has been an increasing fascination with alternative medicine, specifically herbal remedies. The presence of alkaloids in medicinal plants presents a promising prospect for the advancement of novel approaches to diabetes mellitus therapies. The aim of this research is to evaluate the bioactive alkaloid phytoconstituents and their interaction with the α-amylase and α-glucosidase inhibitors using in-silico approach. Results: A total of 49 phytoconstituents were analyzed as potential inhibitors of these enzymes with top 15 selected based on molecular docking studies. Physicochemical properties, ADME (absorption, distribution, metabolism, and excretion) profile, and toxicity predictions were performed to predict pharmacokinetics, drug-likeness, and toxicity. Subsequently, the molecular docking study was performed using Schrodinger software (PDB ID: 3TOP). Piperumbellactam C (− 8.18 kcal/mol) and Trigonelline (− 7.99 kcal/mol). displayed the highest docking score and standard acarbose showed (− 8.97 kcal/mol). The MM-GBSA (Molecular Mechanics, General Born Surface Area) assay showed favorable binding energy. All other phytoconstituents exhibited favorable pharmacokinetic and toxicological parameters and found within acceptable ranges. Further, a 200 ns MD (Molecular Dynamic) Simulation study was carried out in order to check the stability of Piperumbellactam C-3TOP complex. Conclusions: The findings of this research validate the antidiabetic properties of some active alkaloid phytoconstituents and additionally showcase the potential inhibitory activity via in-silico analysis.


  • Open Access

    Hydrazineyl-linked imidazole[1,2-a]pyrimidine-thiazole hybrids: design, synthesis, and in vitro biological evaluation studies

    by Dinesha P, Shivakumar Naik, Udayakumar D, Revanasiddappa B. C, Venkatesh Ranjan, Naveena S. Veeranagaiah

    A new set of imidazo[1,2-a]pyrimidine-thiazole hybrids were developed through a molecular hybridization concept. Three compounds exhibited potent anti-TB activity with MIC of 1.6 μg mL−1.


  • Computational Design of a Multiepitope Vaccine Targeting Rabies Virus Glycoprotein

    by Kavitha Guladahalli Manjunatha, Akhila Dharnappa Sannejal, Mahendra Gowdru Srinivasa, Revanasiddappa Bc, Devananda Devegowda, Sushma Pradeep, Chandan Shivamallu

    Rabies, a neglected tropical disease, persists as a historical health challenge. The glycoprotein (G) gene of the rabies virus is the key antigen providing effective protection. Post-exposure prophylaxis involves vaccination and Rabies Immunoglobulins (RIGs) as per WHO guidelines. Identifying epitopes is crucial for specific immunotherapies. In this study, eight conserved epitopes were identified based on antigenicity, immunogenicity, MHC binding affinity, and IFN-[ ] stimulation. A multiepitope vaccine was constructed and validated for antigenicity, stability, and safety. Protein–protein docking revealed RGP6 and RGP7 as strong candidates, with RGP6 showing the highest docking scores (–7.351 and –5.197) and potential as a novel target epitope for immunotherapy. The molecular dynamics simulations demonstrated that both 6LGX-ligand and 6LGW-ligand complexes maintained structural stability and dynamic equilibrium over the course of the simulation. Further, the binding free energy calculations for 6LGX (–79.440) and 6LGW (–47.338) suggest that the 6LGX-ligand complex is more stable than the 6LGW-ligand complex, as evidenced by their more negative values, indicating greater energy required for dissociation. The study suggests that the multi-epitope subunit vaccine is immunogenic, nonallergic, and capable of eliciting cellular and humoral immune responses.